Lymphoproliferative Disease in the Rectum 4 Years after Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report

Marieke C Barnhoorn; Astrid G S Van Halteren; Melissa Van Pel; Ilse Molendijk; Ada C Struijk; Patty M Jansen; Hein W Verspaget; Gerard Dijkstra; Liesbeth E M Oosten; Andrea E Van der Meulen-de Jong

doi:10.1093/ecco-jcc/jjy220

Lymphoproliferative Disease in the Rectum 4 Years after Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report

Marieke C Barnhoorn
, Astrid G S Van Halteren
, Melissa Van Pel
, Ilse Molendijk
, Ada C Struijk
, Patty M Jansen
, Hein W Verspaget
, Gerard Dijkstra
, Liesbeth E M Oosten
, Andrea E Van der Meulen-de Jong^*

^*Corresponding author for this work

Leiden University Medical Centre
University Medical Centre Groningen
University of Groningen

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

Abstract

Mesenchymal stromal cell [MSC] therapy is a new treatment for perianal fistulas in Crohn's disease. Although MSC therapy shows a favourable safety profile, long-term safety data are limited. We detected an Epstein Barr virus [EBV]-associated B cell lymphoproliferative lesion in the rectum of a patient 4 years after local administration of MSCs for his perianal fistulas. To investigate whether MSC therapy contributed to the development of this lymphoproliferative disease, we analyzed the possibility of EBV transfer via the MSC product and the persistence of MSCs in the lymphoproliferative lesion using short tandem repeat analysis.

Original language	English
Pages (from-to)	807-811
Number of pages	5
Journal	Journal of Crohn's and Colitis
Volume	13
Issue number	6
DOIs	https://doi.org/10.1093/ecco-jcc/jjy220
Publication status	Published - Jun 2019
Externally published	Yes

Bibliographical note

Access to Document

10.1093/ecco-jcc/jjy220

Cite this

Barnhoorn, M. C., Van Halteren, A. G. S., Van Pel, M., Molendijk, I., Struijk, A. C., Jansen, P. M., Verspaget, H. W., Dijkstra, G., Oosten, L. E. M., & Van der Meulen-de Jong, A. E. (2019). Lymphoproliferative Disease in the Rectum 4 Years after Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report. Journal of Crohn's and Colitis, 13(6), 807-811. https://doi.org/10.1093/ecco-jcc/jjy220

@article{646f7a79ea274b69ba1b7cb7b9bbc4f8,

title = "Lymphoproliferative Disease in the Rectum 4 Years after Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report",

abstract = "Mesenchymal stromal cell [MSC] therapy is a new treatment for perianal fistulas in Crohn's disease. Although MSC therapy shows a favourable safety profile, long-term safety data are limited. We detected an Epstein Barr virus [EBV]-associated B cell lymphoproliferative lesion in the rectum of a patient 4 years after local administration of MSCs for his perianal fistulas. To investigate whether MSC therapy contributed to the development of this lymphoproliferative disease, we analyzed the possibility of EBV transfer via the MSC product and the persistence of MSCs in the lymphoproliferative lesion using short tandem repeat analysis.",

author = "Barnhoorn, \{Marieke C\} and \{Van Halteren\}, \{Astrid G S\} and \{Van Pel\}, Melissa and Ilse Molendijk and Struijk, \{Ada C\} and Jansen, \{Patty M\} and Verspaget, \{Hein W\} and Gerard Dijkstra and Oosten, \{Liesbeth E M\} and \{Van der Meulen-de Jong\}, \{Andrea E\}",

note = "Copyright {\textcopyright} 2018 European Crohn{\textquoteright}s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].",

year = "2019",

month = jun,

doi = "10.1093/ecco-jcc/jjy220",

language = "English",

volume = "13",

pages = "807--811",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "6",

}

Barnhoorn, MC, Van Halteren, AGS, Van Pel, M, Molendijk, I, Struijk, AC, Jansen, PM, Verspaget, HW, Dijkstra, G, Oosten, LEM & Van der Meulen-de Jong, AE 2019, 'Lymphoproliferative Disease in the Rectum 4 Years after Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report', Journal of Crohn's and Colitis, vol. 13, no. 6, pp. 807-811. https://doi.org/10.1093/ecco-jcc/jjy220

Lymphoproliferative Disease in the Rectum 4 Years after Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report. / Barnhoorn, Marieke C; Van Halteren, Astrid G S; Van Pel, Melissa et al.
In: Journal of Crohn's and Colitis, Vol. 13, No. 6, 06.2019, p. 807-811.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Lymphoproliferative Disease in the Rectum 4 Years after Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas

T2 - A Case Report

AU - Barnhoorn, Marieke C

AU - Van Halteren, Astrid G S

AU - Van Pel, Melissa

AU - Molendijk, Ilse

AU - Struijk, Ada C

AU - Jansen, Patty M

AU - Verspaget, Hein W

AU - Dijkstra, Gerard

AU - Oosten, Liesbeth E M

AU - Van der Meulen-de Jong, Andrea E

PY - 2019/6

Y1 - 2019/6

N2 - Mesenchymal stromal cell [MSC] therapy is a new treatment for perianal fistulas in Crohn's disease. Although MSC therapy shows a favourable safety profile, long-term safety data are limited. We detected an Epstein Barr virus [EBV]-associated B cell lymphoproliferative lesion in the rectum of a patient 4 years after local administration of MSCs for his perianal fistulas. To investigate whether MSC therapy contributed to the development of this lymphoproliferative disease, we analyzed the possibility of EBV transfer via the MSC product and the persistence of MSCs in the lymphoproliferative lesion using short tandem repeat analysis.

AB - Mesenchymal stromal cell [MSC] therapy is a new treatment for perianal fistulas in Crohn's disease. Although MSC therapy shows a favourable safety profile, long-term safety data are limited. We detected an Epstein Barr virus [EBV]-associated B cell lymphoproliferative lesion in the rectum of a patient 4 years after local administration of MSCs for his perianal fistulas. To investigate whether MSC therapy contributed to the development of this lymphoproliferative disease, we analyzed the possibility of EBV transfer via the MSC product and the persistence of MSCs in the lymphoproliferative lesion using short tandem repeat analysis.

UR - https://www.scopus.com/pages/publications/85066961715

U2 - 10.1093/ecco-jcc/jjy220

DO - 10.1093/ecco-jcc/jjy220

M3 - Article

C2 - 30561580

AN - SCOPUS:85066961715

SN - 1873-9946

VL - 13

SP - 807

EP - 811

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

IS - 6

ER -

Lymphoproliferative Disease in the Rectum 4 Years after Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this